138 related articles for article (PubMed ID: 31690096)
1. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2019 Nov; ():2168479019879380. PubMed ID: 31690096
[TBL] [Abstract][Full Text] [Related]
2. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
3. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
4. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
Rathore AS; Li Y; Chhabra H; Lohiya A
J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
[TBL] [Abstract][Full Text] [Related]
5. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
Bai HK; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
Chatterjee S; Patel HK; Sansgiry SS
Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
8. Analysis of e-cigarette warning letters issued by the Food and Drug Administration in 2020 and 2021.
Schillo BA; Bertrand A; Briggs J; Kierstead EC; Silver NA; Yoon SN; Diaz MC
Tob Control; 2024 Feb; 33(2):247-251. PubMed ID: 36229228
[TBL] [Abstract][Full Text] [Related]
9. Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022.
Dmour I
J Pharm Innov; 2022 Nov; ():1-15. PubMed ID: 36407089
[TBL] [Abstract][Full Text] [Related]
10. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
[TBL] [Abstract][Full Text] [Related]
11. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
12. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
Shetty YC; Saiyed AA
J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
[TBL] [Abstract][Full Text] [Related]
13. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018.
Rogers CA; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2020 Sep; 54(5):1123-1133. PubMed ID: 32096103
[TBL] [Abstract][Full Text] [Related]
14. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
15. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
Garmendia CA; Bhansali N; Madhivanan P
Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
[TBL] [Abstract][Full Text] [Related]
16. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
Mohite N; Funtanilla V; Muzumdar J; Park T
Innov Pharm; 2021; 12(1):. PubMed ID: 34007685
[TBL] [Abstract][Full Text] [Related]
17. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
18. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
[TBL] [Abstract][Full Text] [Related]
19. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
20. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
